Ending the Prescription Drug Kickback Act of 2023

Hozzl · 2023-12-15T16:07:10Z

Explore the details of Senate Bill 1217 Ending the Prescription Drug Kickback Act of 2023 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/15/2023, 4:07 PM

Summary of Bill S 1217

Bill 118 s 1217, also known as the Ending the Prescription Drug Kickback Act of 2023, is a piece of legislation introduced in the US Congress with the aim of addressing the issue of kickbacks in the prescription drug industry.

The bill seeks to prohibit pharmaceutical companies from providing kickbacks or other incentives to healthcare providers in exchange for prescribing their drugs. This practice has been criticized for driving up healthcare costs and potentially compromising patient care by influencing doctors' prescribing decisions.

If passed, the Ending the Prescription Drug Kickback Act of 2023 would impose penalties on pharmaceutical companies found to be engaging in kickback schemes, including fines and potential criminal charges. The bill also includes provisions for increased transparency and reporting requirements to ensure compliance with the new regulations. Overall, the goal of this legislation is to promote fair competition in the prescription drug market and protect patients from potential conflicts of interest that may arise from kickback arrangements between pharmaceutical companies and healthcare providers.

Congressional Summary of S 1217

Ending the Prescription Drug Kickback Act of 2023

This bill generally prohibits prescription drug manufacturers from providing rebates to pharmacy benefit managers (PBMs) or private health insurance plans.

Specifically, the bill eliminates the safe harbor for rebates, or other payments, provided to PBMs that are intended to influence the applicable cost-sharing tier of the drug (e.g., placing the drug in a more favorable formulary tier).

The bill further prohibits health insurance plans from receiving such rebates with respect to a prescription drug covered by the plan. Plans also must ensure PBMs do not receive any such rebates.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 1217

Bill S 1217 is currently in the status of Bill Introduced since April 19, 2023. Bill S 1217 was introduced during Congress 118 and was introduced to the Senate on April 19, 2023. Bill S 1217's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of April 19, 2023